Allogene Therapeutics Inc (ALLO)

02:10 AM

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN

02:10 AM

Jan 29, 2025

Allogene Therapeutics executive to depart, consulting agreement planned - MSN

Jan 29, 2025

Jan 29, 2025

Allogene Therapeutics executive to depart, consulting agreement planned By Investing.com - Investing.com UK

Jan 29, 2025

Jan 29, 2025

Allogene Therapeutics Announces Executive Departure and Transition - TipRanks

Jan 29, 2025

Jan 29, 2025

Allogene’s ALLO-329 gains IND clearance for autoimmune diseases - BioWorld Online

Jan 29, 2025

Jan 29, 2025

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer - GlobeNewswire

Jan 29, 2025

Jan 29, 2025

Manufacturing Expert Who Built Cell Forge 1 Takes Helm as Allogene's New CTO - StockTitan

Jan 29, 2025

Jan 28, 2025

Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial - CRISPR Medicine News

Jan 28, 2025

Jan 28, 2025

Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive™

Jan 28, 2025

Jan 28, 2025

Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate - Marketscreener.com

Jan 28, 2025

Jan 28, 2025

Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL

Jan 28, 2025

Jan 28, 2025

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - The Manila Times

Jan 28, 2025

Jan 28, 2025

Game-Changing Autoimmune Treatment: Allogene's Novel CAR T Targets Both B-cells and T-cells - StockTitan

Jan 28, 2025

Jan 24, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Sells $48,414.22 in Stock - MarketBeat

Jan 24, 2025

Jan 22, 2025

Advancing LBCL Treatment Through MRD Monitoring and Allogeneic CAR T-Cell Therapy - Pharmacy Times

Jan 22, 2025

Jan 20, 2025

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN

Jan 20, 2025

Jan 20, 2025

Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Jan 20, 2025

Jan 15, 2025

Barclays PLC Buys 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Jan 15, 2025

Jan 13, 2025

JPMorgan Chase & Co. Sells 37,348 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Jan 13, 2025

Jan 13, 2025

What is Zacks Research's Forecast for ALLO Q2 Earnings? - MarketBeat

Jan 13, 2025

Jan 12, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $9.73 Consensus Price Target from Brokerages - MarketBeat

Jan 12, 2025

Jan 10, 2025

Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World

Jan 10, 2025

Jan 02, 2025

Geode Capital Management LLC Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Jan 02, 2025

Jan 02, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Holdings Boosted by Geode Capital Management LLC - Defense World

Jan 02, 2025

Dec 26, 2024

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance

Dec 26, 2024

Dec 26, 2024

Oncology In Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Barchart

Dec 26, 2024

Dec 26, 2024

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga

Dec 26, 2024

Dec 24, 2024

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance

Dec 24, 2024

Dec 24, 2024

State Street Corp Has $19.64 Million Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 24, 2024

Dec 18, 2024

Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com

Dec 18, 2024

Dec 18, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 18, 2024

Dec 16, 2024

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2024

Dec 16, 2024

Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Dec 16, 2024

Dec 15, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat

Dec 15, 2024

Dec 15, 2024

Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - MSN

Dec 15, 2024

Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada

Dec 13, 2024

Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa

Dec 13, 2024

Dec 12, 2024

Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com

Dec 12, 2024

Dec 12, 2024

Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector Decline - GuruFocus.com

Dec 12, 2024

Dec 12, 2024

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times

Dec 12, 2024

Dec 12, 2024

Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire

Dec 12, 2024

Dec 11, 2024

Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com

Dec 11, 2024

Dec 11, 2024

Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com

Dec 11, 2024

Dec 10, 2024

Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha

Dec 10, 2024

Dec 10, 2024

Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 10, 2024

Dec 09, 2024

Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com

Dec 09, 2024

Dec 06, 2024

Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 06, 2024